Search over 3,000 reports

    Nonalcoholic Steatohepatitis (NASH) - Market Insights, Epidemiology and Market Forecast - 2027

    Nonalcoholic Steatohepatitis (NASH) - Market Insights, Epidemiology and Market Forecast - 2027
    Date: Dec, 2017
    Type: Pharmaceutical Industry Report
    Pages: 120
    Geography: Global
    Delivery Timeline: 24 Hours
    SKU: DIMI0019

    DelveInsight’s ‘Nonalcoholic Steatohepatitis (NASH)- Market Insights, Epidemiology and Market Forecast-2027’ report provides a disease overview of the Nonalcoholic Steatohepatitis (NASH) along with the epidemiology and the market scenario in the 7MM – United States, EU5 (Germany, France, Spain Italy , United Kingdom) and Japan. 
    The Report covers the therapeutics market revenue, treatment practice and Nonalcoholic Steatohepatitis (NASH) forecasted market share from 2017 to 2027 segmented by seven major markets. In addition, the report also includes global forecast of epidemiology of Nonalcoholic Steatohepatitis (NASH) till 2027. Our epidemiology forecast covers the prevalent population as well as the diagnosed population having Nonalcoholic Steatohepatitis (NASH).

    The report also covers the detailed market size forecast for 7MM. According to DelveInsight, it is estimated that the market size of Nonalcoholic Steatohepatitis (NASH) in 7MM shall increase and reach up to 49.25 Billion in 2027, with the compound annual growth rate (CAGR) of 23.0% for the period i.e., 2015-2027. 

    Nonalcoholic Steatohepatitis (NASH) is a subtype of NAFLD (Nonalcoholic Fatty Liver Disease) that is characterized by accumulation of large amount of fat in the liver, along with inflammation and scarring. NASH is one of the most common liver related health problem and is considered to be strongly associated with insulin resistance,  central obesity, reduced glucose tolerance, type 2 diabetes mellitus (T2DM), arterial hypertension, and hypertriglyceridemia. The condition can further progress to cirrhosis, liver failure and rarely liver cancer.

    Key Coverage and Benefits:
    • The report will help in developing business strategies by understanding the trends shaping and driving the global Nonalcoholic Steatohepatitis (NASH) market.
    • Organize sales and marketing efforts by identifying the best opportunities for Nonalcoholic Steatohepatitis (NASH) in US, European Union 5 (EU5- Germany, Spain, Italy, France and United Kingdom) and Japan. 
    • To understand the future market competition in the global Nonalcoholic Steatohepatitis (NASH) market and Insightful review of the key market drivers and barriers.
    • To understand the regulatory scenario in major markets.

    1. Report Introduction
    2. Non-Alcoholic Steatohepatitis Market Overview at a Glance
    3. Total Market Share Distribution of Non-Alcoholic Steatohepatitis for 7 MM in 2016
    4. Total Market Share Distribution of Non-Alcoholic Steatohepatitis for 7 MM in 2027
    5. Non-Alcoholic Steatohepatitis

    5.1. Introduction
    5.2. Types
    5.3. Classification of NASH: Stages of Fibrosis
    5.4. Causes
    5.5. Pathophysiology
    5.6. Symptoms
    5.7. Diagnosis
    6. Epidemiology and Patient Population
    7. Key Points:
    8. Population and Forecast Parameters
    9. Prevalent Population of NASH in 7MM
    10. Region-Wise Prevalent Population of NASH
    11. Diagnosed Population of NASH in 7MM
    12. Region-Wise Diagnosed Population of NASH

    12.1. United States
    12.1.1. Prevalent Population of NASH
    12.1.2. Diagnosed Population of NASH
    12.2. Germany
    12.2.1. Prevalent Population of NASH
    12.2.2. Diagnosed Population of NASH
    12.3. France
    12.3.1. Prevalent Population of NASH
    12.3.2. Diagnosed Population of NASH
    12.4. Italy
    12.4.1. Prevalent Population of NASH
    12.4.2. Diagnosed Population of NASH
    12.5. Spain
    12.5.1. Prevalent Population of NASH
    12.5.2. Diagnosed Population of NASH
    12.6. United Kingdom
    12.6.1. Prevalent Population of NASH
    12.6.2. Diagnosed Population of NASH
    12.7. Japan
    12.7.1. Prevalent Population of NASH
    12.7.2. Diagnosed Population of NASH
    13. Treatment Algorithm
    14. American Association for the Study of Liver Diseases (AASLD) Current Recommendations for NAFLD/NASH
    15. EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
    16. Guideline for NAFLD/NASH, by the Japanese Society of Gastroenterology (JSG) in cooperation with “The Japan Society of Hepatology”
    17. Unmet Needs
    18. Emerging Drugs

    18.1. Phase-III Drugs Analysis
    18.2. Phase-II Drugs Analysis
    19. Emerging Therapies
    19.1. Elafibranor(GFT505): GenfitPharma
    19.1.1. Regulatory Milestones
    19.1.2. Other development activities
    19.1.3. Clinical Development
    19.1.4. Ongoing Trials Information
    19.1.5. Safety and Efficacy
    19.1.6. Advantages and Disadvantages
    19.1.7. Product Profile
    19.2. Obeticholic Acid (OCA): Intercept Pharmaceuticals, Inc.
    19.2.1. Regulatory milestones
    19.2.2. Other development activities
    19.2.3. Clinical Development
    19.2.4. Ongoing Trials Information
    19.2.5. Safety and Efficacy
    19.2.6. Advantages and Disadvantages
    19.2.7. Product Profile
    19.3. Selonsertib (Ask-1 Inhibitor): Gilead Sciences, Inc.
    19.3.1. Other development activities
    19.3.2. Clinical Development
    19.3.3. Clinical Pipeline Activity
    19.3.4. Safety and Efficacy
    19.3.5. Advantages and Disadvantages
    19.3.6. Product Profile
    19.4. Cenicriviroc (CVC): Allergan/Tobira Therapeutics
    19.4.1. Regulatory milestones
    19.4.2. Other development activities
    19.4.3. Clinical Development
    19.4.4. Ongoing Trials Information
    19.4.5. Safety and Efficacy
    19.4.6. Advantages and Disadvantages
    19.4.7. Product Profile
    19.5. NGM282: NGM Biopharmacueticals, Inc.
    19.5.1. Other development activities
    19.5.2. Clinical Development
    19.5.3. Ongoing Trials Information
    19.5.4. Safety and Efficacy
    19.5.5. Advantages and Disadvantages
    19.5.6. Product Profile
    19.6. BMS-986036: Bristol-Myers Squibb Company
    19.6.1. Other development activities
    19.6.2. Clinical Development
    19.6.3. Ongoing trials information
    19.6.4. Safety and Efficacy
    19.6.5. Advantages and Disadvantages
    19.6.6. Product Profile
    19.7. Emricasan: Conatus Pharmaceuticals Inc.
    19.7.1. Regulatory milestones
    19.7.2. Other development activities
    19.7.3. Clinical Development
    19.7.4. Ongoing trials information
    19.7.5. Safety and Efficacy
    19.7.6. Product Profile
    19.8. IVA337: Inventiva Pharma
    19.8.1. Regulatory milestones
    19.8.2. Clinical Development
    19.8.3. Ongoing trial information
    19.8.4. Safety and Efficacy
    19.8.5. Product Profile
    20. Nonalcoholic Steatohepatitis (NASH): Country-Wise Market Analysis
    20.1. Total Market Size of Nonalcoholic Steatohepatitis (NASH) for 7 MM in 2015-2027
    21. United States
    21.1. Market Size of NASH in United States
    22. Europe
    23. Germany

    23.1. Market Size of NASH in Germany
    24. France
    24.1. Market Size of NASH in France
    25. Italy
    25.1. Market Size of NASH in Italy
    26. Spain
    26.1. Market Size of NASH in Spain
    27. United Kingdom
    27.1. Market Size of NASH in United Kingdom
    28. Japan
    28.1. Market Size of NASH in Japan
    29. Market Drivers
    30. Market Barriers
    31. Appendix
    32. Report Methodology
    33. Consulting Services
    34. Disclaimer
    35. About DelveInsight

    Table 1: Total Prevalent Population of NASH in 7 MM (2015-2027)
    Table 2: Region-Wise Prevalent Population of NASH (2015-2027)
    Table 3: Total Diagnosed Population of NASH in 7 MM (2015-2027)
    Table 4: Region-Wise Diagnosed Population of NASH (2015-2027)
    Table 5: Prevalent Population of NASH based on Fibrosis Score in United States (2015-2027)
    Table 6: Diagnosed Population of NASH in United States (2015-2027)
    Table 7: Prevalent Population of NASH based on Fibrosis Score in Germany (2015-2027)
    Table 8: Diagnosed Population of NASH in Germany (2015-2027)
    Table 9: Prevalent Population of NASH based on Fibrosis Score in France (2015-2027)
    Table 10: Diagnosed Population of NASH in France (2015-2027)
    Table 11: Prevalent Population of NASH based on Fibrosis Score in Italy (2015-2027)
    Table 12: Diagnosed Population of NASH in Italy (2015-2027)
    Table 13: Prevalent Population of NASH based on Fibrosis Score in Spain (2015-2027)
    Table 14: Diagnosed Population of NASH in Spain (2015-2027)
    Table 15: Prevalent Population of NASH based on Fibrosis Score in United Kingdom (2015-2027)
    Table 16: Diagnosed Population of NASH in United Kingdom (2015-2027)
    Table 17: Prevalent Population of NASH based on Fibrosis Score in Japan (2015-2027)
    Table 18: Diagnosed Population of NASH in Japan (2015-2027)
    Table19 : Treatment Algorithm of Nonalcoholic Steatohepatitis (NASH)
    Table20 : Medications for Nonalcoholic Steatohepatitis (NASH)
    Table 21 : Management of NAFLD based on histology
    Table 22 : AASLD Current Recommendations for NAFLD/NASH
    Table 23 : EASL–EASD–EASO Clinical Practice Guidelines for the management of NAFLD
    Table 24 : Guideline for NAFLD/NASH, by the Japanese Society of Gastroenterology (JSG)
    Table 25: Market Size of Nonalcoholic Steatohepatitis (NASH) in 7MM (USD Billion) (2015-2027)
    Table 26: United States Market Size of Nonalcoholic Steatohepatitis (NASH) in USD, Billion (2015-2027)
    Table 27: Germany Market Size of Nonalcoholic Steatohepatitis (NASH) in USD, Billion (2015-2027)
    Table 28: France Market Size of Nonalcoholic Steatohepatitis (NASH) in USD, Billion (2015-2027)
    Table 29: Italy Market Size of Nonalcoholic Steatohepatitis (NASH) in USD, Billion (2015-2027)
    Table 30: Spain Market Size of Nonalcoholic Steatohepatitis (NASH) in USD, Billion (2015-2027)
    Table 31: United Kingdom Market Size of Nonalcoholic Steatohepatitis (NASH) in USD, Billion (2015-2027)
    Table 32: Japan Market Size of Nonalcoholic Steatohepatitis (NASH) in USD, Billion (2015-2027)

     

    Figure 1: Types of NASH
    Figure 2: Stages of NASH
    Figure 3: Classification of NASH
    Figure 4: Pathophysiology of NASH
    Figure 5: Pathophysiology of NASH: Lipolysis of adipose tissue
    Figure 6: Pathophysiology of NASH: Dietary factors
    Figure 7: Pathophysiology of NASH: Kupffer cells
    Figure 8: Total Prevalent Population of NASH in 7 MM (2015-2027)
    Figure 9: Region-Wise Prevalent Population of NASH (2015-2027)
    Figure 10: Total Diagnosed Population of NASH in 7 MM (2015-2027)
    Figure 11: Region-Wise Diagnosed Population of NASH (2015-2027)
    Figure 12: Prevalent Population of NASH based on Fibrosis Score  in United States (2015-2027)
    Figure 13: Diagnosed Population of NASH in United States (2015-2027)
    Figure 14: Prevalent Population of NASH based on Fibrosis Score in Germany (2015-2027)
    Figure 15: Diagnosed Population of NASH in Germany (2015-2027)
    Figure 16: Prevalent Population of NASH based on Fibrosis Score  in France (2015-2027)
    Figure 17: Diagnosed Population of NASH in France (2015-2027)
    Figure 18: Prevalent Population of NASH based on Fibrosis Score  in Italy (2015-2027)
    Figure 19: Diagnosed Population of NASH in Italy (2015-2027)
    Figure 20: Prevalent Population of NASH based on Fibrosis Score  in Spain (2015-2027)
    Figure 21: Diagnosed Population of NASH in Spain (2015-2027)
    Figure 22: Prevalent Population of NASH based on Fibrosis Score in United Kingdom (2015-2027)
    Figure 23: Diagnosed Population of NASH in United Kingdom (2015-2027)
    Figure 24: Prevalent Population of NASH based on Fibrosis Score in Japan (2015-2027)
    Figure 25: Diagnosed Population of NASH in Japan (2015-2027)
    Figure 26: Unmet needs: NASH
    Figure 27: United States Market Size of Nonalcoholic Steatohepatitis (NASH) in USD, Billion (2015-2027)
    Figure 28: Germany Market Size of Nonalcoholic Steatohepatitis (NASH) in USD, Billion (2015-2027)
    Figure 29: France Market Size of Nonalcoholic Steatohepatitis (NASH) in USD, Million (2015-2027)
    Figure 30:Italy Market Size of Nonalcoholic Steatohepatitis (NASH) in USD, Billion (2015-2027)
    Figure 31:Spain Market Size of Nonalcoholic Steatohepatitis (NASH) in USD, Billion (2015-2027)
    Figure 32: United Kingdom Market Size of Nonalcoholic Steatohepatitis (NASH) in USD, Million (2015-2027)
    Figure 33:Japan Market Size of Nonalcoholic Steatohepatitis (NASH) in USD, Million (2015-2027)
    Figure 34: Market Drivers: NASH
    Figure 35:Market Barriers: NASH

     

    Nonalcoholic Steatohepatitis (NASH) Market (7MM)

    Nonalcoholic Steatohepatitis (NASH) Market forecasting

    Nonalcoholic Steatohepatitis (NASH) Sales forecasting

    Nonalcoholic Steatohepatitis (NASH) Market segments

    Nonalcoholic Steatohepatitis (NASH) Epidemiology

    Nonalcoholic Steatohepatitis (NASH) Pipeline products and technologies

    Nonalcoholic Steatohepatitis (NASH) Competitive landscape

    Nonalcoholic Steatohepatitis (NASH) SWOT analysis

    Nonalcoholic Steatohepatitis (NASH) Market Driver's and barriers

    Nonalcoholic Steatohepatitis (NASH) Key Companies and Funding



    • Single User License
      (20% Off)
      $5,750.00
    • Site License
      (30% Off)
      $11,500.00
    • Global License
      (40% Off)
      $17,250.00

    Contact Us

    Phone
    +91-11-45689769, +91 9650213330

    Email
    info@delveinsight.com

    Address
    New Delhi-110075, India

    Latest Tweets

    • Copyright © 2017 Delveinsight.
    • Sitemap